Habit, prejudice, power and politics: Issues in the conversion of H2-receptor antagonists to over-the-counter use

CMAJ. Canadian Medical Association Journal

Volumn 154, Issue 1, 1996, Pages 49-53

  Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST;

CANADA; DRUG EFFICACY; DYSPEPSIA; EDITORIAL; HABIT; HEARTBURN; POLITICS; PRESCRIPTION; SOCIAL PSYCHOLOGY;

EID: 0030023005     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Editorial

References (40)

1. Morgan PP, Cohen L: Off the prescription pad and over the counter: the trend toward drug deregulation grows. Can Med Assoc J 1995; 152: 387-389
2. 2-receptor antagonists safe over the counter drugs? [editorial] BMJ 1994; 309: 493-494
3. Spencer JA, Edwards C: Pharmacy beyond the dispensary: general practitioners' views. BMJ 1992; 304: 1670-1672
4. Jones RH: Is anxiety justified on latest OTC moves? MIMS Mad Wkly 1994; Jan 25: 12-13
5. Colin-Jones DG: When should endoscopy (or radiology) be used in dyspepsia and peptic ulcer disease? Ali Pharmacol Ther 1987; 1 (suppl 1): 548S-555S
6. Colin-Jones DG, Bloom B, Bodemar G et al: Management of dyspepsia: report of a working group. Lancet 1988; 1: 576-579
7. Talley NJ, Colin-Jones D, Kock KL et al: Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145-160
8. Talley NJ, Fett SL, Zinsmeister AR et al: Gastrointestinal tract symptoms and self reported abuse: a population-based study. Gastroenterology 1994; 107: 1040-1049
9. Singh S, Richter JE, Bradley LA et al: The symptom index: differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci 1993; 38: 1402-1408
10. Jones RH, Lydeard SE: Prevalence of symptoms of dyspepsia in the community. BMJ 1989; 298: 30-32
11. Jones RH, Lydeard SE: Dyspepsia in the community. Br J Clin Pract 1992; 46: 95-97
12. Kay L, Jorgensen T: Epidemiology of upper dyspepsia in a random population: prevalence, incidence, natural history and risk factors. Scand J Gastroenterol 1994; 29: 2-6
13. Tasch RF, Fenton A: Incidence of common gastrointestinal complaints and patient treatment patterns in Canada. [abstract] Pharmacoepidemiol Drug Safety 1995; 4 (suppl 1): S51
14. Bennett E, Beaurepaire J, Langeluddecke P et al: Life stress and non-ulcer dyspepsia: a case-control study. J Psychosom Res 1991; 35: 579-590
15. 2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status. Pharmacol Toxicol 1991; 69: 253-258
16. 2-receptor antagonists. Drug Saf 1993; 8: 179-185
17. Compuscript IMS, Intercontinental Medical Statistics of Canada, Mississauga, Ont, Dec 1994
18. Simon TJ, Gardner AH, Stauffer LA et al: Self directed treatment of intermittent heartburn: a randomized multicenter double blind placebo controlled evaluation of famotidine 5, 10, 20 mg and antacid. [abstract] Gastroenterology 1994; 106: A181
19. Johannessen T, Fjosne U, Kleveland PM et al: Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol 1988; 23: 327-336
20. Gotthard R, Bodemar G, Brodin U et al: Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23: 7-18
21. Talley NJ, McNeil D, Hayden A et al: Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986; 91: 149-156
22. Mackinnon M, Willing RL, Whitehead R: Cimetidine in the management of symptomatic patients with duodenitis: a double-blind controlled trial. Dig Dis Sci 1982; 27: 217-219
23. Nesland AA, Berstad A: Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1985; 20: 629-635
24. Delattre M, Malesky M, Prinzie A: Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Curr Ther Res Clin Exp 1985; 37: 980-991
25. Singal AK, Kumar A, Broor SL: Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo controlled study. Curr Med Res Opin 1989; 11: 390-397
26. 2-blockers. Med Care 1990; 28: 834-852
27. Colin-Jones DG, Langman MJS, Lawson DH: Cimetidine and gastric cancer: preliminary report from post marketing surveillance study. BMJ 1982; 285: 1311-1313
28. Colin-Jones DG, Langman MJS, Lawson DH: Post marketing surveillance of the safety of cimetidine: mortality during second, third and fourth years of follow up. BMJ 1985; 291: 1084-1088
29. Das A, Freston JW, Jacobs J: An evaluation of safety in 37 252 patients treated with cimetidine or ranitidine. Int Med Spec 1990; 11: 127-149
30. 2-receptor antagonists. Arch Intern Med 1993; 154: 2415-2424
31. 2-receptor antagonists: standard therapy for acid-peptic diseases. [review, two parts] N Engl J Med 1990; 323: 1672-1680, 1749-1755
32. American College of Physicians Health and Public Policy Committee: Endoscopy in the evaluation of dyspepsia. Ann Intern Med 1985; 102: 266-269
33. Porter JB, Jick H, Perera DR et al: Long term follow up study of cimetidine. Pharmacotherapy 1984; 4: 361-364
34. Schumacher MJ, Jick SJ, Jick H: Cimetidine use and gastric cancer. Epidemiology 1990; 1: 251-254
35. Rios-Castellanos E, Sitas F, Shepherd NA: Changing pattern of gastric cancer in Oxfordshire. Gut 1992; 33: 1312-1317
36. Sue-Ling HM, Martin I, Griffith J et al: Early gastric cancer: 46 cases treated in one surgical department. Gut 1992; 33: 1318-1322
37. 2-receptor antagonists How will they affect the treatment of acid related diseases? Drugs 1994; 47: 1-11
38. Bernerson B, Johnsen R, Bostad L: Is Helicobacter pylori the cause of dyspepsia? BMJ 1992; 304: 1276-1279
39. 2-receptor antagonist (famotidine). Am J Ther 1995; 2: 304-313
40. Schiller LR, Fordtran JS. Ulcer complications during short-term therapy of duodenal ulcer with active agents and placebo. Gastroenterology 1986; 90: 478-481